About UsMeet Prolong Pharmaceuticals
Prolong Pharmaceuticals, LLC (Prolong)
is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing differentiated products that treat prevalent conditions and address unmet medical needs and orphan diseases. Headquartered in South Plainfield, New Jersey, Prolong is committed to developing novel biologics to treat several diseases and their debilitating comorbidities associated with reduced quality of life, increased medical cost, and significant mortality. The Company is currently developing a portfolio of products in stroke, hematology, and oncology.
Originally established in 2005 as a research lab, Prolong has emerged as a mature, privately held biotech company with an active clinical development program and has a large-scale cGMP manufacturing facility on-line.
The Founders of Prolong were among the pioneers in PEGylation achieving the first regulatory approval of a PEGylated protein therapeutic (Adagen, Enzon, 1990).
The chemistry of “PEG” has exploded since this product launch such that now there exists a near infinite pallet of chemical linkers and molecular sizes for PEGylation considerations. This PEGylation technology is responsible for the development of many drugs aiming to improve the quality of life for sufferers of hepatitis, kidney disease, and several other life-threatening diseases.
PEGfinity™ was created at Prolong to leverage the prior PEGylation experience and, in combination with in-silico analysis methods, to achieve comprehensive PEGylation coverage of the entire protein in rapid order. Drug library generation and lead candidate selection follows an iterative structure/function analytical process that is specifically defined for each protein and clinical indication.
Meet Our Team ⟶
Our Pipeline ⟶
If you have any questions regarding our products or services, please contact us by phone or by completing the contact form and we will respond to your inquiry at the earliest convenience.
300 Corporate Court, Suite B
South Plainfield, NJ 07080 USA
Expanded Access Policy
Prolong Pharmaceuticals, LLC does not provide any drug in development to patients unless they have been accepted into one of our ongoing clinical trials. For more information on our ongoing clinical trials, please contact email@example.com